01477.HK
Ocumension Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 5.37
+1.23%Year over year
Reported trailing growth
- Revenue
- +183.9%
- EBITDA
- +61.2%
- EBIT
- +49.6%
- EPS
- +57.2%
- Free cash flow
- +40.0%
- Operating cash flow
- +76.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +71.7%
- EBITDA
- +84.1%
- EBIT
- +47.7%
- Net income
- +40.8%
- EPS
- +48.7%
- Free cash flow
- +12.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026